Late Effects research
The Late Effects Clinic is involved in a broad range of research activities with a range of collaborators including prevalence of late effects after stem cell transplantation with an emphasis on cardiovascular risk factors and metabolic health. Psychosocial needs of long-term cancer survivors and quality of life measurements are also a focus of ongoing research and data collection.
Achievements
2010: Victorian Public Healthcare Awards, Premier's Excellence Award Improving Cancer Care in Victoria category-Highly Commended. “Improving Quality of Life for Long Term cancer Survivors through support services”
2013: Monash Alfred Psychiatry Research Centre Prize. Impact of pre-transplant psychological distress and coping style on self-reported QoL in long-term survivors of allogeneic SCT
2014: Tour de Cure–Tour recipient, Late Effects Clinic
2014: Henrietta Law Memorial Prize for Allied Health Research. Positive Change for Life. Preliminary results of a 12-month lifestyle intervention program on metabolic syndrome risk factors in haemopoietic SCT survivors
2015: Victorian Public Healthcare Awards: Key Directions in Healthcare Awards–Minister of Health’s Award for excellence in cancer care - "Positive Change for Life"
Current research
ReCHARGE: Online self-management of cancer-related fatigue
Fatigue is a common and distressing long-term effect of cancer treatment and significantly affects quality of life. It is a complex problem and medications are mostly ineffective. The management of fatigue therefore represents a critical unmet need for cancer survivors.
Find out moreNutrition in the management of long term survivors
Impact of nutritional intervention in the outpatient management of long term survivors of haematological malignancy treated with stem cell transplantation.
Find out morePartners
Publications
Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia
Fleming S, Ong DM, Jackson K, Avery S, Mollee P, Marlton P, Kennedy G, Wei AH
(2017), Br J Haematol, 177(2), 328-30
The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study
Tan P, Soo Tiong I, Fleming S, Pomilio G, Cummings N, Droogleever M, McManus J, Schwarer A, Catalano J, Patil S, Avery S, Spencer A, Wei A
(2017), Oncotarget,
Impact of allogeneic hematopoietic stem cell transplantation on the HIV reservoir and immune response in three HIV infected individuals
Koelsch KK, Rasmussen TA, Hey-Nguyen WJ, Pearson C, Xu Y, Bailey M, Marks KH, Sasson SC, Taylor MS, Tantau R, Obeid S, Milner B, Morrissey CO, Pinto AN, Suzuki K, Busch MP, Keating SM, Kaiser P, Yukl S, Wong JK, Hiener BM, Palmer S, Zaunders J, Post JJ, Chan DJ, Avery S, Milliken ST, Kelleher AD, Lewin SR, Cooper DA
(2017), J Acquir Immune Defic Syndr,